SUSTAINED RELEASE TABLET FOR ORAL USE

摘要

[PROBLEMS] To provide a sustained release tablet for oral use which causes no rapid increase in the concentration of 4-(2-methyl-1-imidazolyl) -2,2-diphenylbutylamide (KRP-197) in the blood at the early stage of the administration and makes it possible to maintain an appropriate concentration thereof in the blood over a long period of time. [MEANS FOR SOLVING PROBLEMS] A sustained release tablet for oral use characterized by being obtained by adding a gel-forming substance to a medicinal composition containing KRP-197 as the active ingredient.